TWI902669B - 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 - Google Patents
抗金黃色葡萄球菌凝集因子a(clfa)之抗體Info
- Publication number
- TWI902669B TWI902669B TW108126187A TW108126187A TWI902669B TW I902669 B TWI902669 B TW I902669B TW 108126187 A TW108126187 A TW 108126187A TW 108126187 A TW108126187 A TW 108126187A TW I902669 B TWI902669 B TW I902669B
- Authority
- TW
- Taiwan
- Prior art keywords
- ser
- antibody
- antigen
- thr
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702762P | 2018-07-24 | 2018-07-24 | |
| US62/702,762 | 2018-07-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202019956A TW202019956A (zh) | 2020-06-01 |
| TWI902669B true TWI902669B (zh) | 2025-11-01 |
Family
ID=67539640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108126187A TWI902669B (zh) | 2018-07-24 | 2019-07-24 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11155606B2 (https=) |
| EP (1) | EP3840838A2 (https=) |
| JP (2) | JP7525471B2 (https=) |
| CN (2) | CN112672788B (https=) |
| AU (1) | AU2019309366B2 (https=) |
| BR (1) | BR112021001214A2 (https=) |
| CA (1) | CA3107463A1 (https=) |
| MX (1) | MX2021000889A (https=) |
| TW (1) | TWI902669B (https=) |
| WO (1) | WO2020023644A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX375324B (es) | 2012-11-06 | 2025-03-06 | Medimmune Llc | Anticuerpos contra determinantes de la superficie de s. aureus. |
| DE102018115012A1 (de) | 2018-06-21 | 2019-12-24 | Carl Zeiss Microscopy Gmbh | Teilchenstrahlsystem |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| MX2021004114A (es) | 2018-10-09 | 2021-07-16 | Medimmune Llc | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| TWI743626B (zh) | 2019-01-24 | 2021-10-21 | 德商卡爾蔡司多重掃描電子顯微鏡有限公司 | 包含多束粒子顯微鏡的系統、對3d樣本逐層成像之方法及電腦程式產品 |
| DE102019008249B3 (de) | 2019-11-27 | 2020-11-19 | Carl Zeiss Multisem Gmbh | Teilchenstrahl-System mit einer Multistrahl-Ablenkeinrichtung und einem Strahlfänger, Verfahren zum Betreiben des Teilchenstrahl-Systems und zugehöriges Computerprogrammprodukt |
| AU2024269156A1 (en) * | 2023-05-09 | 2026-01-08 | Astrazeneca Ab | Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014074540A2 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Antibodies to s. aureus surface determinants |
| WO2015175874A2 (en) * | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PT1377314E (pt) * | 2001-01-26 | 2012-01-02 | Inhibitex Inc | Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| EP1479695B1 (en) | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| EP2043690A1 (en) | 2006-06-12 | 2009-04-08 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| ES2650224T3 (es) | 2007-08-21 | 2018-01-17 | Amgen, Inc. | Proteínas de unión al antígeno C-FMS humano |
| EP2185190B1 (en) | 2007-08-31 | 2015-06-24 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| CN102171247A (zh) | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN104119438A (zh) | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| US8609102B2 (en) | 2009-05-18 | 2013-12-17 | Julius-Maximilians-Universitat | Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of ISAA or ISAB |
| RU2677140C1 (ru) | 2010-05-05 | 2019-01-15 | Нью-Йорк Юниверсити | Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение |
| EP3470526A3 (en) | 2011-02-08 | 2019-07-17 | Medimmune, LLC | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| MX357938B (es) | 2011-06-19 | 2018-07-31 | Univ New York | Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas. |
| RU2654596C2 (ru) | 2012-03-19 | 2018-05-21 | Текнифар-Индустриа Текника Фармасеутика С.А. | Композиции коктейля, содержащие антибактериальные фаги, и способы их применения |
| US9845348B2 (en) | 2012-11-06 | 2017-12-19 | Medimmune, Llc | Methods of treating S. aureus-associated diseases |
| EP3057989A1 (en) | 2013-10-17 | 2016-08-24 | ARSANIS Biosciences GmbH | Cross-reactive staphylococcus aureus antibody sequences |
| MX2016007533A (es) | 2013-12-09 | 2016-12-14 | Univ New York | Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos. |
| MX2016007212A (es) | 2013-12-19 | 2016-09-07 | Arsanis Biosciences Gmbh | Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos. |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| MX2017012775A (es) | 2015-04-17 | 2019-04-29 | Arsanis Biosciences Gmbh | Preparacion combinatoria de anticuerpos anti-staphylococcus aureus. |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| MX2021004114A (es) | 2018-10-09 | 2021-07-16 | Medimmune Llc | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
-
2019
- 2019-07-24 TW TW108126187A patent/TWI902669B/zh active
- 2019-07-24 CN CN201980058857.XA patent/CN112672788B/zh active Active
- 2019-07-24 EP EP19749544.3A patent/EP3840838A2/en active Pending
- 2019-07-24 AU AU2019309366A patent/AU2019309366B2/en active Active
- 2019-07-24 MX MX2021000889A patent/MX2021000889A/es unknown
- 2019-07-24 US US16/521,223 patent/US11155606B2/en active Active
- 2019-07-24 CA CA3107463A patent/CA3107463A1/en active Pending
- 2019-07-24 BR BR112021001214-1A patent/BR112021001214A2/pt unknown
- 2019-07-24 WO PCT/US2019/043254 patent/WO2020023644A2/en not_active Ceased
- 2019-07-24 CN CN202411220211.6A patent/CN119176871A/zh active Pending
- 2019-07-24 JP JP2021503901A patent/JP7525471B2/ja active Active
-
2021
- 2021-09-23 US US17/483,162 patent/US11970527B2/en active Active
-
2024
- 2024-03-28 JP JP2024053871A patent/JP2024105229A/ja active Pending
- 2024-03-29 US US18/621,921 patent/US20240352098A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014074540A2 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Antibodies to s. aureus surface determinants |
| WO2015175874A2 (en) * | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
Also Published As
| Publication number | Publication date |
|---|---|
| US11155606B2 (en) | 2021-10-26 |
| WO2020023644A3 (en) | 2020-03-19 |
| BR112021001214A2 (pt) | 2021-04-27 |
| JP7525471B2 (ja) | 2024-07-30 |
| CA3107463A1 (en) | 2020-01-30 |
| US20240352098A1 (en) | 2024-10-24 |
| US11970527B2 (en) | 2024-04-30 |
| EP3840838A2 (en) | 2021-06-30 |
| JP2024105229A (ja) | 2024-08-06 |
| TW202019956A (zh) | 2020-06-01 |
| WO2020023644A2 (en) | 2020-01-30 |
| US20200048330A1 (en) | 2020-02-13 |
| CN119176871A (zh) | 2024-12-24 |
| US20220073595A1 (en) | 2022-03-10 |
| CN112672788B (zh) | 2024-09-17 |
| JP2021530244A (ja) | 2021-11-11 |
| KR20210035846A (ko) | 2021-04-01 |
| AU2019309366A1 (en) | 2021-02-18 |
| CN112672788A (zh) | 2021-04-16 |
| AU2019309366B2 (en) | 2025-06-05 |
| MX2021000889A (es) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI902669B (zh) | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 | |
| JP6473746B2 (ja) | 交差反応性黄色ブドウ球菌抗体配列 | |
| US11168133B2 (en) | Combinations of anti-Staphylococcus aureus antibodies | |
| JP6251730B2 (ja) | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 | |
| JP7459075B2 (ja) | スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 | |
| KR20170136637A (ko) | 항-스타필로코커스 아우레우스 항체 배합 제제 | |
| CN106132988A (zh) | 抗金黄色葡萄球菌lukgh(lukab)毒素的抗体和抗体序列 | |
| WO2020033926A9 (en) | Antibodies that bind cd277 and uses thereof | |
| KR102955585B1 (ko) | 에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체 | |
| RU2818805C2 (ru) | АНТИТЕЛО, НАПРАВЛЕННОЕ ПРОТИВ ФАКТОРА СЛИПАНИЯ А (ClfA) S. aureus | |
| RU2804815C2 (ru) | Комбинации антител к staphylococcus aureus | |
| CA2958018A1 (en) | Anti-ospa antibodies and methods of use | |
| WO2020033925A2 (en) | Antibodies that bind cd277 and uses thereof |